Avacta Group (LON:AVCT) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

Avacta Group Plc (LON:AVCT) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 69.75 and traded as high as GBX 70. Avacta Group shares last traded at GBX 68.50, with a volume of 1,622,167 shares.

Avacta Group Price Performance

The company has a market cap of £313.93 million, a price-to-earnings ratio of -6.94 and a beta of 1.12. The company has a fifty day simple moving average of GBX 69.60 and a two-hundred day simple moving average of GBX 69.73. The company has a quick ratio of 4.96, a current ratio of 0.89 and a debt-to-equity ratio of 602.46.

Avacta Group (LON:AVCT) last released its quarterly earnings results on Tuesday, May 19th. The biotechnology company reported GBX (9.27) earnings per share (EPS) for the quarter. Avacta Group had a negative return on equity of 2,929.47% and a negative net margin of 33,961.06%.The firm had revenue of GBX 11 million for the quarter. On average, equities research analysts anticipate that Avacta Group Plc will post -9.9011833 earnings per share for the current fiscal year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).